236 related articles for article (PubMed ID: 17894369)
1. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations.
Adi H; Traini D; Chan HK; Young PM
J Pharm Sci; 2008 Jul; 97(7):2780-8. PubMed ID: 17894369
[TBL] [Abstract][Full Text] [Related]
2. Micro-particle corrugation, adhesion and inhalation aerosol efficiency.
Adi S; Adi H; Tang P; Traini D; Chan HK; Young PM
Eur J Pharm Sci; 2008 Sep; 35(1-2):12-8. PubMed ID: 18586091
[TBL] [Abstract][Full Text] [Related]
3. Use of solid corrugated particles to enhance powder aerosol performance.
Chew NY; Chan HK
Pharm Res; 2001 Nov; 18(11):1570-7. PubMed ID: 11758765
[TBL] [Abstract][Full Text] [Related]
4. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
5. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation.
Traini D; Young PM; Jones M; Edge S; Price R
Eur J Pharm Sci; 2006 Feb; 27(2-3):243-51. PubMed ID: 16330191
[TBL] [Abstract][Full Text] [Related]
7. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
Lucas P; Anderson K; Staniforth JN
Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
[TBL] [Abstract][Full Text] [Related]
8. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
9. Lactose composite carriers for respiratory delivery.
Young PM; Kwok P; Adi H; Chan HK; Traini D
Pharm Res; 2009 Apr; 26(4):802-10. PubMed ID: 19015956
[TBL] [Abstract][Full Text] [Related]
10. Scanning white-light interferometry as a novel technique to quantify the surface roughness of micron-sized particles for inhalation.
Adi S; Adi H; Chan HK; Young PM; Traini D; Yang R; Yu A
Langmuir; 2008 Oct; 24(19):11307-12. PubMed ID: 18759384
[TBL] [Abstract][Full Text] [Related]
11. Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy.
Traini D; Scalia S; Adi H; Marangoni E; Young PM
Int J Pharm; 2012 Nov; 438(1-2):150-9. PubMed ID: 22964399
[TBL] [Abstract][Full Text] [Related]
12. Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems.
Ooi J; Traini D; Hoe S; Wong W; Young PM
Int J Pharm; 2011 Jul; 413(1-2):1-9. PubMed ID: 21501674
[TBL] [Abstract][Full Text] [Related]
13. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
14. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics.
Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
Jones MD; Buckton G
Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
[TBL] [Abstract][Full Text] [Related]
16. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
17. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
Sethuraman VV; Hickey AJ
AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
[TBL] [Abstract][Full Text] [Related]
18. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations.
Traini D; Young PM; Thielmann F; Acharya M
Drug Dev Ind Pharm; 2008 Sep; 34(9):992-1001. PubMed ID: 18800259
[TBL] [Abstract][Full Text] [Related]
19. Dry powder aerosol delivery systems: current and future research directions.
Chan HK
J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
[TBL] [Abstract][Full Text] [Related]
20. Force control and powder dispersibility of spray dried particles for inhalation.
Weiler C; Egen M; Trunk M; Langguth P
J Pharm Sci; 2010 Jan; 99(1):303-16. PubMed ID: 19533606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
